IPS Therapeutique is a specialty Contract Research Organization which dedicates its expertise and technology to the evaluation of the cardiac safety of new drugs at an early stage of their development, by using validated and highly predictive models.
Recognized for the quality and the on-time delivery of its IND enabling studies, IPS Therapeutique addresses the particular needs of start-up and mature biopharmaceutical companies which are looking for fast and cost-effective solutions to assess the QT Prolongation and the arrhythmogenic liability of their new compound(s) during preclinical development